Analyst Research
| Report Title | Price |
|---|---|
|
Trading Report for (SNY). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
|
Provider: Market Edge
|
$10.00
|
|
Provider: Finlabo SIM Spa
|
$10.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
FDA Approves Sanofi SA's and Regeneron Pharmaceuticals Inc's Zaltrap for Metastatic Colorectal Cancer-Reuters
Reuters reported that the U.S. Food and Drug Administration has approved Sanofi SA's and Regeneron Pharmaceuticals Inc's Zaltrap for use in combination with a folinic acid, fluorouracil and irinotecan chemotherapy regimen to treat adults with colorectal cancer.
Latest Developments for Sanofi SA
- Sanofi SA Wins Japanese Government's Approval for Lyxumia Drug-Reuters
- Sanofi SA to Cut 207 Research Posts in France; Updates on Toulouse Site-Agence France Press
- Sanofi SA Announces Phase 3 Results for Investigational New Insulin U300
- Sanofi SA and Takeda Pharmaceutical Co Ltd Sets up Joint Venture- SeeNews
Latest Key Developments in Pharmaceuticals
- Biogen Idec Inc And Swedish Orphan Biovitrum AB Presents New Data From Phase 3 Study Of Long-Lasting Hemophilia Factor Candidate ALPROLIX
- Medicines Co Announces Positive Results For Solo II Trial Of Oritavancin In Treatment Of Acute Bacterial Skin And Skin Structure Infections
- OHKI CO LTD Announces Concern of Uncollectible or Delayed Receivables
- CKD Bio Announces Resignation of Co-CEO
- Share this
- Link this
- Digg this
Follow Reuters